Navigation Links
Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
Date:4/5/2011

inances in general, as well as risks and uncertainties associated with the Company's VMAT2 program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's VMAT2 program include, but are not limited to; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate partners for development, commercial manufacturing and marketing and sales activities for the Company's partnered programs; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2010. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
2. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
3. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
4. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
5. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
6. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
8. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
9. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
10. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
11. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015  BioClinica®, Inc., a leading specialty ... announced that clinical trial professionals representing 20 ... annual European User Conference in ... use of its eClinical technologies to overcome ... the Microsoft Office-Smart OnPoint CTMS; Express EDC; ...
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ... of yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular ... expected late 2016.   SARAH, a large ... cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, ...
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... molecular diagnostics that target the underlying mechanisms of cancer, ... period ended December 31, 2014. Effective July ... from May 31 to December 31. As a result ... are for the quarter and the seven months ended ...
(Date:3/3/2015)... 03, 2015 Experts and industry insiders ... one event: the Alltech REBELation exploring innovation, inspiration and ... Now in its 31st year, Alltech’s annual international conference ... and the opportunity to join the REBELation at an ... 11:59 p.m. EST, at which point the standard early ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... Md., Aug. 6 ImQuest BioSciences announced,today ... National Institutes of,Health to support the development ... topical microbicide product. ImQuest and a consortium ... will,develop a highly innovative product from the ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" ... its pressure cycling technology ("PCT")-enhanced,trypsin digestion application for ... of products. Named "Proteolysis (Trypsin)-PrEP", this new,PCT-enhanced processing ... Development of Innovative Therapeutics Expo 2008, being held,this ...
... Integrated Nanochannel Chip and Reader for,Single-Molecule Mapping, Enabling Direct ... Strands of DNA in Context and ... BioNanomatrix, Inc., a developer,of breakthrough nanoscale whole genome ... today announced,receipt of a grant from the National Human ...
Cached Biology Technology:ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission 2ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission 3Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 2Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 3Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 4Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics 5BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications 2BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications 3
(Date:2/25/2015)... Feb. 25, 2015  ABC Financial Services (ABC), ... the Health and Fitness Industry, today announced enhancements ... MYiCLUBonline.  The latest upgrade includes advances to the ... cardless check-in via Identity One fingerprint biometrics. The ... through interactive displays at the International Health, Racquet ...
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/18/2015)... 18, 2015  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. , ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern ... Orlando, FL Wednesday, March 4, 2015 at 10.25 ... the live webcasts for these events, please visit Cepheid,s website ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Cepheid to Webcast Upcoming Financial Presentations 2
... with salty, undrinkable water for fish production is ... be an effective potential alternative livelihood for people ... drylands. In a report released today, researchers ... on Agricultural Research in Dryland Areas (ICARDA), and ...
... CLEVELAND November 10, 2008 A multidisciplinary research team ... Ph.D., a professor in the School of Medicine,s Department ... a number of birth defects that affect the development ... jaw, palate, brain and heart are relatively common congenital ...
... of invasive marine is one of many research results ... the First World Conference on Marine Biodiversity, Ciudad de ... report that invasive species of marine macroalgae spread at ... that covered by invasive terrestrial plants. The difference ...
Cached Biology News:'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 2'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 3'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 4'Arid aquaculture' among livelihoods promoted to relieve worsening pressure on world's drylands 5Case Western Reserve University uncovers genetic basis for some birth defects 2Marine invasive species advance 50km per decade, World Conference on Marine Biodiversity told 2Marine invasive species advance 50km per decade, World Conference on Marine Biodiversity told 3Marine invasive species advance 50km per decade, World Conference on Marine Biodiversity told 4
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
... ScriptCap™ 2'-O-Methyltransferase converts Cap 0 (or Cap ... Cap 1 structure has been shown to ... to 50%. This improvement is seen in ... m7G Capping System as well as those ...
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
Biology Products: